W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT.
Cheng Yang,Walter M. Stadler,Gregory S. Karczmar,Michael Milosevic,Michael Milosevic,Ivan Yeung,Ivan Yeung,Masoom A. Haider +7 more
TL;DR: Close correlation of quantitative parameters derived from two independent imaging modalities suggests both are measuring similar tumor physiologic variables.
Journal ArticleDOI
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
Andrew S. Artz,K. van Besien,Todd M. Zimmerman,Thomas F. Gajewski,Brian I. Rini,H. S. Hu,Walter M. Stadler,N. J. Vogelzang +7 more
TL;DR: Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there are limited long-term follow-up data.
Journal ArticleDOI
Samarium-153-EDTMP (Quadramet ® ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
Christopher R. Heery,Ravi A. Madan,Mark N. Stein,Walter M. Stadler,Robert S. DiPaola,Robert S. DiPaola,Myrna Rauckhorst,Seth M. Steinberg,Jennifer L. Marte,Clara C. Chen,Italia Grenga,Renee N. Donahue,Caroline Jochems,William L. Dahut,Jeffrey Schlom,James L. Gulley +15 more
TL;DR: The results of this phase 2 multi-center trial provide the rationale for clinical evaluation of new radiopharmaceuticals, such as Ra-223, in combination with PSA-TRICOM.
Journal ArticleDOI
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Brian I. Rini,Susan Halabi,Robert C. Barrier,Kim Margolin,David Avigan,Theodore F. Logan,Walter M. Stadler,Philip L. McCarthy,Charles A. Linker,Eric J. Small +9 more
TL;DR: A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach.
Journal ArticleDOI
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Eric Jonasch,Walter M. Stadler,Ronald M. Bukowski,Teresa G. Hayes,Atul Varadhachary,Rajesh Malik,Robert A. Figlin,Sandy Srinivas +7 more
TL;DR: The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC).